Regular ArticleTreatment of Advanced or Recurrent Endometrial Carcinoma with Single-Agent Carboplatin
References (0)
Cited by (73)
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: A Japanese Gynecologic Oncology Group study (JGOG2041)
2011, Annals of OncologyCitation Excerpt :Treatment of advanced or recurrent endometrial carcinoma most commonly involves chemotherapy, but the fact remains that chemotherapy for endometrial carcinoma may be no more than a palliative measure. The drugs for which efficacy has been studied in monotherapy for endometrial carcinoma include cisplatin, carboplatin, doxorubicin, epirubicin, and 5-fluorouracil, for which the reported response rates are 4%–42% [5–7], 28%–33% [8, 9], 37% [10], 26% [11], and 41% [12], respectively. Of these, it is presently considered that cisplatin and doxorubicin, which have relatively high response rates, and which have been studied extensively, are the key drugs for endometrial carcinoma.
Management of Advanced-Stage and Recurrent Endometrial Cancer
2009, Seminars in OncologyPaclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study
2008, Gynecologic OncologyCitation Excerpt :For the small proportion of women who have advanced or recurrent disease, treatment with hormonal or chemotherapeutic agents, alone or in combination, can be considered [4–7]. Single agents with demonstrable objective responses in at least 20% of patients include taxanes, anthracyclines, and platinum compounds [7–15]. Also, a number of combination regimens have been explored over the last two decades, most in uncontrolled trials.
Carboplatin and paclitaxel in advanced or metastatic endometrial cancer
2008, Gynecologic OncologySystemic therapy in metastatic or recurrent endometrial cancer
2007, Cancer Treatment ReviewsCitation Excerpt :Carboplatin given at doses of 300–400 mg/m2 has been associated with RRs of 29%.76–78 Burke et al.76 prospectively treated 33 patients with advanced primary tumors or recurrent disease with 360 mg/m2 CBDCA given intravenously every 28 days. Nine of 27 patients (33%) with measurable disease had objective responses, including three complete and six partial responses.